Abstract
Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.
MeSH terms
-
Administration, Oral
-
Aged
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Humans
-
Liver Neoplasms / drug therapy*
-
Male
-
Thalidomide / administration & dosage
-
Thalidomide / therapeutic use*
-
Tomography, X-Ray Computed
-
Treatment Outcome
-
alpha-Fetoproteins / metabolism
Substances
-
Angiogenesis Inhibitors
-
alpha-Fetoproteins
-
Thalidomide